BY JAKE POINIER

W ith the arrival of 2013,

Banner MD Anderson

Cancer Center in Gilbert

will be expanding its world-class offer-

ings in two key areas: Head and neck

cancer surgeries and oncology, and

stem cell transplantation. While the

programs are different from a medical

perspective, they have one essential

element in common: integrated

teams with national expertise in their

respective fields.

“Integration is one of the important

things that makes the Banner MD

Anderson approach different,” says

head and neck surgeon Thomas D.

Shellenberger, M.D., who has helped

start up the program. He has been both

at The University of Texas MD Ander-

son Cancer Center and MD Anderson

Cancer Center Orlando for a decade,

where he headed up the creation of

their head and neck program. “Rela-

tive to other cancers, head and neck

cancer requires numerous disciplines

and subspecialties in addition to radia-

tion oncology, medical oncology, and

surgery in order to be successful.”

For example, Dr. Shellenberger

cites speech pathology, dental oncol-

ogy, and nutritional consultation, as

well as collaboration with plastic and

reconstructive surgeons. “It’s not just

about curing the cancer, but how can

we help patients retain maximum

quality of life,” he says.

JANUARY 2013A PUBLICATION FOR COMMUNITY PHYSICIANS

Thomas D. Shellenberger M.D. and Klaus Wagner M.D.

INSIDE2 Stem cell program, transplant options3 Changing the surgical landscape4 Meet Drs. Craft and Tan5 New hope for pancreatic cancer patients

6 What’s happening at Banner MD Anderson7 Rare pregnancy cancer is curable8 Banner MD Anderson physicians

Integrated approachesFirst look at Banner MD Anderson Cancer Center’s new head and neck cancer and stem cell transplant programs

2 JANUARY 2013 ROUNDS

HEAD AND NECK CANCERKlaus Wagner, M.D., the team’s medical

oncologist, notes an increasing preva-

lence of head and neck cancer. “In the

past, these types of tumors were smok-

ing and alcohol related,” he says. “We’re

seeing more head and neck cases that

are HPV related, and we’re also seeing

them in younger patients.”

The head and neck program will be

increasing its capabilities in the coming

year, including the addition of robotic

surgery. On the oncology side, Dr. Wagner

will be adding state-of-the-art diagnostic

imaging as well as multimodality thera-

pies such as monoclonal antibodies.

“Cetuximab can be a good alternative to

chemotherapy, with fewer side effects, or

as a synergizer with radiation, particu-

larly for those who have tolerance issues

with chemotherapy,” he said.

Finally, the program will be launch-

ing prospective research trials in 2013.

“Head and neck cancers really don’t

form one disease but a group of diseases

that are individually rare, so there’s a lot

of heterogeneity,” Dr. Shellenberger says.

“We will be studying

treatment regimens

to determine which

ones lead to im-

proved outcomes,

with specific strate-

gies to objectively

study quality indica-

tors in a prospective

way to chart the

course of how the

program develops. The head and neck

program at MD Anderson Houston is a

world leader, and our task is to follow

that lead and meet that high standard.”

STEM CELL TRANSPLANT PROGRAMThe launch of the Stem Cell Transplant

program offers new hope for Arizonans

with leukemia, lymphoma, multiple

myeloma, myelodysplastic syndrome,

and other hematologic and bone mar-

row failure disorders. Heading up the

program is Gorgun Akpek, M.D., M.H.S.,

a nationally recognized stem cell

transplant physician whose background

includes work with the Bone Marrow

Transplantation program at Johns Hop-

kins University and the University of

Maryland Greenebaum Cancer Center,

an NCI-designated cancer center.

“I’m excited to translate my experi-

ence and background into building

a program in a timely fashion and

providing the best transplant care in

Arizona,” Akpek says. “We’re currently

in the process of aligning our guidelines

and standard operating procedures

with MD Anderson, since we have very

similar treatment goals and care sets.”

Akpek expects to announce trans-

Javier Munoz M.D., and Gorgun Akpek M.D., M.H.S.

plant activities starting in January or

February, and is in the process of hiring

two additional transplant physicians. The

program will start with autologous trans-

plants, using a patient’s own stem cells.

Allogeneic transplants, using cells from a

related or matched donor, are expected

to be added by summer 2013.

TRANSPLANT OPTIONS The upper age for eligibility is expected to

be 75 for autologous transplants and 70 for

allogeneic transplants, with the possibility

of increasing those ages in the future.

The transplant program will work in

concert with Javier Munoz, M.D., staff

physician in hematology and oncol-

ogy who has trained at MD Anderson

Houston, and handles patients with

hematological malignancies including

lymphomas, many of whom eventu-

ally need transplants. “Lymphoma is

a heterogeneous disease, and there

are multiple variables that determine

which patients will truly benefit from a

particular treatment including targeted

therapy with monoclonal antibodies or

antibody-drug conjugates,” said Munoz.

“We formed a hematology tumor board

in which different specialists review cases

in a multidisciplinary fashion to tailor the

best treatment regimen for each patient.”

Optimally, physicians should refer

patients to Akpek for a transplant consul-

tation early in the course of the disease.

“Most of the time we are a last resort,

after many treatments and after the dis-

ease becomes resistant,” he says. “Even

if a patient doesn’t meet the criteria, the

earlier the referral the better.”

It’s not just about curing

the cancer, but how can we help

patients retain maximum

quality of life.

— Thomas D. Shellenberger, M.D.

DID YOU KNOW?MD Anderson Houston is one of the largest centers in the world for stem cell transplants — performing more than 865 procedures for adults and children each year, more than any other center in the nation.

DID YOU KNOW?According to the American Cancer Society, more than 52,000 men and women in the U.S. were diagnosed with head and neck cancers in 2012.

BannerMDAnderson.com 3

BY DEBRA GELBART

Two plastic surgeons at Banner

MD Anderson Cancer Center in

Gilbert recently began perform-

ing the latest in autologous breast recon-

struction surgery for cancer patients.

Unlike a TRAM flap that depends

on the rectus for a blood supply when

the tissue is relocated, the Deep Inferior

Epigastric Perforator (DIEP) reconnects

abdominal skin and fat to the internal

mammary artery. The rectus is left intact.

A by-product of the procedure is

improved abdominal contour, which en-

genders increased patient satisfaction.

Changing the surgical landscapeNew era in autologous breast reconstruction comes to Banner MD Anderson Cancer Center

GIVING PATIENTS MORE OPTIONS“The DIEP has not been widely avail-

able before now,” said reconstructive

surgeon Benny Tan, M.D. “We want

to give more patients an opportunity

to choose this approach to breast re-

construction.” He and reconstructive

surgeon Randall Craft, M.D. typically

perform the surgery together.

Both practice in Banner MD

Anderson’s Division of Surgical Oncol-

ogy as plastic and reconstructive

surgeons. Unilateral reconstruction

takes between six and eight hours;

bilateral reconstruction can take up

to 12 hours.

With a traditional TRAM flap, the

surgical impact on the rectus often

results in bulging of the abdomen,

hernias or weakness, Drs. Tan and

Craft said. “But by leaving the rectus

intact,” Dr. Craft said, “we can often

give patients a better quality of life.”

NO AUTOMATIC AGE RESTRICTIONNot all patients are candidates for

the DIEP, Dr. Tan said, explaining

that sometimes a patient’s vessels

are too small to accommodate the

reattached tissue. “Although there

is no age cutoff,” he said “a patient

must be physiologically fit enough

4 JANUARY 2013 ROUNDS

to endure a six-to-12-hour surgery,

depending on whether the recon-

struction is unilateral or bilateral.”

A patient can’t be morbidly obese

or especially thin. Her ideal BMI is

between 25 and 35, he said, so that

she has enough abdominal tissue to

be used for the reconstruction. And,

ideally, she has not had previous

abdominal surgery, although a C-

section or a previous hernia surgery

or laparoscopic cholecystectomy, for

example, would not preclude a DIEP.

The post-surgical hospital stay is

typically four to seven days.

This procedure is well-suited

for a patient who has undergone

radiation therapy, Dr. Craft said.

Susan Brown*, 50, of Chandler, had

been a radiation therapy patient,

so she wasn’t a good candidate for

implant surgery. She was referred

to Dr. Craft for the DIEP. “I would

tell other breast cancer patients to

strongly consider this procedure,”

Brown said. “It’s tough, because of

the length of the surgery, but it’s well

worth it. I am so grateful to have a

natural-looking and natural-feeling

breast again and I really like knowing

I won’t need another surgery in 10

years like I would with an implant.”

For patients who are not good

candidates for the DIEP, Drs. Craft

and Tan perform autologous breast

reconstruction options, including

the latissimus dorsi flap, TRAM flaps

and implant reconstruction.

Drs. Craft and Tan estimate that

between 25 and 40 percent of all

breast reconstruction patients ulti-

mately will choose the DIEP for their

breast reconstruction. Even if they are

good candidates for the procedure,

however, some patients will opt for

implant surgery or another autolo-

gous reconstruction surgery because

of the complexity of the DIEP.

* Not patient’s real name.

Randall Craft, M.D. became interested in the Deep Inferior Epigastric Perforator (DIEP) procedure while he was a surgical resident in the Harvard Plastic Surgery Combined Residency Program in Boston, Mass. “They did a high volume of these in the Harvard system,” he said, “and I was able to learn a lot about the procedure. Since then, I’ve published a lot about it in the medical literature.” Dr. Craft, who is board-certified in surgery, said he’s always “been drawn to the creativity of plastics. “There’s nothing routine about it, and I like the reconstruc-tive aspects of this type of surgery.” Most of his patients undergo breast reconstruc-tion, but he also performs reconstructive surgery on any part of the body affected by cancer. After graduating from medical school at The Ohio State University College of Medicine in Columbus, he completed his general surgery residency at Mayo Clinic Arizona before beginning his plastic surgery residency at Harvard. He also completed a combined research and clinical fellowship at the Bernard O’Brien Institute of Microsurgery in Melbourne, Australia. Dr. Craft said the most rewarding aspect of performing the DIEP is “provid-ing an opportunity for women to have their sense of self restored,” he said, “without having a foreign body inside them. “The DIEP preserves the symmetry of the chest and patients are typically quite happy with the outcome.”

Benny Tan, M.D. was born and raised in Singapore. At 21, he went to Ireland to attend medical school. After graduation and a general surgery and orthopedic surgery residency, he came to the United States and completed a three-year general surgery residency at Johns Hopkins Hospital in Bal-timore, followed by two years of a general surgery residency at Massachusetts General Hospital in Boston. He then completed an orthopedic hand and microsurgery fellow-ship at Jackson Memorial Hospital in Miami, Fla., followed by a plastic surgery residency at the Cleveland Clinic Florida in Weston, Fla. He is board certified in plastic surgery and general surgery. “I performed many types of reconstruc-tive surgery,” Dr. Tan said, “but I gravitated toward breast reconstruction because the patients are so appreciative when we’re able to give them back their normal life.” He said he began performing the DIEP procedure at Banner MD Anderson because of patient demand. Like Dr. Craft, Dr. Tan also performs implant- and autologous-based breast reconstruction. Dr. Tan noted that DIEP patients also appreciate the extra benefit of the tummy tuck that comes with the procedure. He said both the chest and abdominal scars are well-tolerated by patients. “They also like that their abdominal contour is improved,” he said. “It’s a change most patients are very happy with.”

Contact Drs. Tan and Craft at 480-256-3609.

Doctors well-trained, skilled in performing DIEP

BannerMDAnderson.com 5

BY BETH LIPHAM

I nnovative treatments and a

brighter sense of hope are on the

horizon for pancreatic cancer

patients as Banner MD Anderson

Cancer Center in Gilbert begins a

series of clinical trials.

Pancreatic cancer is one of the

deadliest cancers of our time, with

approximately 42,000 new cases diag-

nosed annually in the United States

resulting in 35,000 deaths. Diagnos-

ing pancreatic cancer is difficult

because symptoms such as low back

pain, indigestion and gastrointestinal

complaints could be mistaken for

other common conditions such as

peptic ulcer, gastritis or arthritis. Un-

fortunately, once detected, pancre-

atic cancer is often advanced and not

curable. Only 20 percent of patients

are candidates for surgery, and only

20 percent of those that have surgery

survive up to 5 years after diagnosis.

PATIENT ACCESSTomislav Dragovich M.D., division

chief of Medical Oncology and Hema-

tology, feels patients with this deadly

disease should be offered access

to clinical trials because standard

therapies are just not good enough.

Current research focuses on breaking

down the complex genetic code of

pancreatic cancer and finding

new anti-cancer drugs (“targeted

therapies”) for pancreatic cancer.

“We are just beginning to see

the fruition of years of continued

research efforts with some more

recent studies showing promise,”

Dragovich says. “A combination

regimen called FOLFIRINOX, for the

first time extended the survival of

patients with metastatic pancreatic

cancer to beyond 11 months. This is

now accepted as a good option for

some patients (those with a good

performance status). And adding

a new drug, nab-paclitaxel (Abrax-

ane), to the current standard therapy

(gemcitabine) also appears to extend

survival of patients with metastatic

disease.

“The complete results from this

trial will be presented at a national on-

cology meeting (ASCO GI Symposium)

in January,” say Dragovich, who par-

ticipated as an investigator in this trial.

“These are incremental but significant

improvements for our patients.”

RESULTS ARE ENCOURAGINGThe Banner MD Anderson team is en-

couraged by the pace of new research

concepts introduced for patients

with pancreatic cancer. Some of the

research treatments are now available

at Banner MD Anderson. Dragovich

is the principal investigator on two

such trials for patients in whom the

standard treatment has failed.

The first trial investigates an

anti-cancer drug called MM398. This

is a chemotherapy drug packaged in

nano-liposomes, which coat the drug

to allow for better penetration inside

pancreatic cancer tissue.

The second trial is a radio-immu-

notherapy trial. It exploits a novel ap-

proach where antibodies are tagged

with a radioactive head that links to a

protein (PAM4) on the surface of the

pancreatic cell much like a “lock and

key” system. “The antibody attaches

to the cancer cell and unloads the

radiation to selectively target and kill

cancer cells,” Dragovich says.

While these are promising and

intriguing concepts, they still need

to be proven in clinical trials. “We

are proud to offer state-of-the art

treatment but also to go beyond that

and provide access to clinical trials

to patients suffering from this dis-

ease. We are encouraged with some

recent results generated by clinical

trials,” he says.

To refer a patient, contact Banner MD Anderson Cancer Center at 480-256-3433. To learn more about pancreatic cancer therapy, read Dragovich’s recent review online at emedicine.medscape.com/article/280605-treatment. He can be reached at 480-256-3335.

New hopefor pancreatic cancer patientsCancer clinical trials open at Banner MD Anderson Cancer Center

Tomislav Dragovich M.D.

6 JANUARY 2013 ROUNDS

T he start of a

new year is a

time to con-

sider our personal

and professional

goals, to reflect and

to dream.

Our patients

will resolve to live

better and to fight

their cancer, and it is our privilege

to stand by them and arm them

with the tools to survive and thrive.

One reason we’re so successful at

Banner MD Anderson Cancer Center

in Gilbert is because of our focus on

the continuum of care.

We are not isolated providers.

We are a team that works together.

Physicians, nurses, researchers,

pharmacists and staff are all es-

sential, because without this team

approach to cancer care, the quality

of care suffers.

From the very first diagnostic test

to treatment and beyond, excellent

communication is critical to pro-

viding outstanding care along the

continuum. One place we see this

working very well is with our gyne-

cologic oncology program, led by

Diljeet Singh, M.D.

In the past, the Valley has been

traditionally underserved in this

area. But with this program and our

experienced gynecologic oncologists,

we are changing that. The presence

of large specialty medical centers like

ours helps to ensure that patients can

experience the continuum of care

— working with the same team from

diagnosis through survivorship. Plus,

with the growth of the gynecologic

oncology program, we also expect to

bring more clinical trials to the Valley.

As we look ahead to this year,

I’m also excited to see the Banner MD

Anderson Stem Cell Transplant pro-

gram continue to grow and evolve

under the leadership of Gorgun

Akpek, M.D. It’s a tremendous step

forward to be able to offer this to

patients with leukemia, lymphoma,

multiple myeloma and other hemato-

logic conditions stem cell transplanta-

tion as part of their treatment.

I’m also eager to watch as our

head and neck program, led by

Thomas Shellenberger, M.D.,

continues to grow as well. In fact,

this March, we expect to see another

surgeon join the team, which already

includes talented radiation and

medical oncologists, allowing us to

offer a full range of care.

This year promises to be an

exciting one, and each and every

one of you plays a critical role in the

continuum of care and the quality

of care we as a team provide. Thank

you for all you do, and I look forward

to building on our successes in 2013!

Sincerely,

Edgardo Rivera, M.D.Medical Director

What’s happening at Banner MD Anderson Cancer Center

BY DR. EDGARDO RIVERA, MEDICAL DIRECTOR

BannerMDAnderson.com 7

BY BRIAN SODOMA

There are plenty of concerns for

a mother to be. Unfortunately

there are also those rare in-

stances when thinking about cribs and

diapers is suddenly cancelled out by

cancer treatment.

That’s the case with the rare but

curable Choriocarcinoma, a type of Ges-

tational Trophoblastic Neoplasia (GTN).

ABNORMAL ACTIVITYGTN occurs when placental tissue

grows abnormally during a pregnancy.

The most common type of GTN is a

hydatidiform mole, also known as a

molar pregnancy. In rare cases, molar

pregnancies can become malignant,

leading to choriocarcinoma.

“The good thing is [choriocarci-

noma] is very sensitive to chemother-

apy. Even stage three can be cured,”

says Dr. Matthew Schlumbrecht, a

gynecologic cancer specialist at

Banner MD Anderson Cancer Center

in Gilbert who has seen about

15 choriocarcinoma cases in his career.

GTN occurs in about 2 in 1,000 preg-

nancies, with choriocarcinoma being

only a small fraction of GTN cases. In all

cases of GTN, the pregnancy is nonviable.

But the good news is that most women

can conceive again after treatment. There

is no prevention strategy for choriocarci-

noma. More than anything, the condition

seems to be a case of bad luck.

SEEING THE MARKERSDoctors are usually tipped off to the

condition during an ultrasound, which

will reveal abnormal tissue in the

uterus. A blood test showing high hCG

(beta human chorionic gonadotropin)

levels is the biggest clue. Abnormal

vaginal bleeding, pelvic pain, and an

abnormal uterine size can also be

present. During treatment, βhCG levels

are monitored closely as a sign that

the condition is receding. Though rare,

GTN can recur after initial diagnosis,

so it is important that patients follow

up closely with their doctors.

Those at greatest risk for the condi-

tion are Asian women, folate-deficient

women, and those having babies at the

extremes of child-bearing age, either

under 20 or over 45 years. Obstetri-

cian/gynecologists are well-trained

at detecting the disease, according to

Schlumbrecht, who also said only a

small number of patients with GTN

even require chemotherapy.

“Most patients end up doing really,

really well with this,” he says.

Rare pregnancy cancer

is curable Choriocarcinoma occurs in 2 of 1,000 pregnancies

The good thing is [choriocarcinoma] is very sensitive to chemotherapy. Even stage three can be cured.

— Dr. Matthew Schlumbrecht

Going into medicine was an easy choice for someone like Dr. Matthew Schlumbrecht. The gynecological cancer specialist at Banner MD Anderson in Gilbert was driven by the intellec-tual challenge and a desire to help others.

Today, Schlumbrecht finds great intel-lectual challenge specializing in malignan-cies of the female genital tract. He has been awarded The University of Texas MD Anderson’s Jesse H. Jones Fellowship Award for excellence and unique contribu-tions to cancer education and has also won MD Anderson’s Gynecologic Oncol-ogy Fellow of the Year recognition.

Schlumbrecht is also working on doctor-focused cancer survivorship research. He has conducted numerous surveys of primary care physicians, internists and those in other disciplines, asking them to assess their strengths and weaknesses in working with cancer survivors.

By 2020, there will be some 20 million cancer survivors in the U.S. After success-ful treatment, these patients must then use these primary care physicians, internists and other disciplines for their health care needs instead of their oncologists, a transition, Schlumbrecht says, that can be difficult.

“There’s a lot of anxiety for patients leaving their oncologist. It’s a much more complicated problem than one would think,” he said.

He is also working to establish a robotic surgery database for the surgery division at Banner MD Anderson to conduct research in the rapidly growing field of minimally invasive surgery. Partnered with MD Anderson’s Houston facility, the data from such a venture will aid in tracking patient outcomes from new surgical approaches.

Meet Dr. Matthew Schlumbrecht

PRESORTED STD

U.S. POSTAGE

PAID

LONG BEACH, CA

PERMIT NO.1677

Banner MD Anderson Cancer Center Physicians

HEMATOLOGY & MEDICAL ONCOLOGY SECTION

Tomislav Dragovich, M.D., PhD, Division Chief Digestive tract cancers including colorectal, esophageal, stomach, pancreatic, hepatobiliary

Gorgun Akpek, M.D., M.H.S.Director of Stem Cell Transplantation and Cellular Therapy program

Shakeela Bahadur, M.D.Lung, colorectal, breast cancers

Mary Cianfrocca, D.O.Breast Cancer Program Director

Farshid Dayyani, M.D., PhDGenitourinary and Gastrointestinal cancers

Jade Homsi, M.D.Melanoma, sarcoma, immunotherapy

H. Uwe Klueppelberg, M.D., PhDMultiple myeloma and other plasma cell disorders, lymphomas, myelodysplastic syndrome, brain cancers, head and neck cancers, thoracic cancers

Javier Munoz, M.D.Lymphoma and other blood cancers

Edgardo Rivera, M.D. Medical Director Breast cancer

Kerry Tobias, DOPain management, palliative medicine, physical medicine, rehabilitation

Klaus Wagner, M.D., PhDThoracic and Head & Neck Cancers

Bryan Wong, M.D.Genitourinary cancers ONCOLOGY SURGERY SECTION

Judith K. Wolf, M.D. Division Chief Gynecologic oncology

Stephanie Byrum, M.D.Breast surgery

Al Chen, M.D.General Surgery

Randall Craft, M.D.Full spectrum of both implant-based and autologous breast reconstruction, comprehensive plastic and reconstructive options for all areas of the body

Mark Gimbel, M.D.Melanoma, sarcoma, cancer of the stomach, small bowel, colon and rectum, thyroid, pancreas, liver and other rare cancers

Matthew Schlumbrecht, M.D., M.P.H.Gynecologic oncology; gestational trophoblastic disease; a variety of surgical techniques including radical abdominopelvic exploration and minimally invasive procedures.

Rob Schuster, M.D.General surgery

Thomas Shellenberger, M.D. Recurrent thyroid cancers, cancers of the oral cavity, oropharynx, and larynx, salivary gland cancers, advanced skin cancers and melanoma of the head and neck, complications from treatment of head and neck cancer.

Diljeet Singh, M.D.Program Director, Gynecologic Oncology; Program Director, Cancer Prevention & Integrative Medicine

Benny Tan, M.D.Plastic and reconstruction surgeonBreast cancer reconstruction and most forms of cancer reconstruction

RADIATION ONCOLOGY SECTION

Matthew Callister, M.D. Division ChiefGastrointestinal, skin, sarcomas and head and neck cancers

Dan Chamberlain, M.D.Thoracic and head and neck malignancies, and body radiosurgery

Emily Grade, M.D.Breast treatment including partial breast brachytherapy, prostate brachytherapy, gynecological and thyroid cancers

Terence Roberts, M.D., J.D.Brain, lung and prostate tumors; stereotactic radiosurgery; partial breast brachytherapy

DIAGNOSTIC IMAGING SECTION

Donald Schomer, M.D. Division Chief CAQ Neuroradiology Oncologic diseases of the brain, spine, head and neck

John Chang, M.D., PhDAdvanced MR and CT imaging of gastrointestinal and genitourinary systems; imaging guided biopsies

Vilert Loving, M.D.Breast imaging and intervention

Harvinder Maan, M.D. CAQ NeuroradiologyDirector of Neuroradiology Neuroradiology and interventional spine procedures

Rizvan Mirza, M.D.Abdominal and pelvic magnetic resonance imaging

Susan Passalaqua, M.D.Director of Nuclear Medicine and Molecular Imaging Oncologic imaging, nuclear medicine, radiology, PET/CT

Andrew Price, M.D., C.A.Q. Interventional radiology, including percutaneous tumor ablation, chemoembolization, and radioembolization David Russell, M.D., F.A.C.P.Breast imaging and intervention

CRITICAL CARE SECTION

Shiva Birdi, M.D., Division ChiefJijo John, M.D.Deven S. Kothari, M.D.Dean Prater, M.D.Ravindra Gudavalli, M.D.

INTERNAL MEDICINE SECTION

Nikunj Doshi, D.O., Division ChiefShefali Birdi, M.D.David Edwards, M.D.Ronald Servi, D.O.

PATHOLOGY SECTION

Kevin McCabe, D.O. Division Chief

Banner MD Anderson Cancer Center in Gilbert physicians are highly specialized in

their fields of expertise. Below is a listing of physicians currently on our full time staff.

Physicians continue to join Banner MD Anderson, so this list will continue to evolve.

To make a referral to a physician on our staff, please call 480-256-3433. To contact a member of medical staff, call 480-256-6444 and ask for the physician to be paged.